Examining blood vessel changes in advanced glaucoma patients
Study of OCT Peripapillary Angiography in Patients With Advanced Glaucoma
This study is testing how changes in blood vessels around the optic nerve affect vision loss in people with advanced glaucoma over three years.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Nantes University Hospital Academic / other |
| Locations | 2 sites (Nantes and 1 other locations) |
| Trial ID | NCT06274593 on ClinicalTrials.gov |
What this trial studies
This study aims to analyze the progression of advanced glaucoma by comparing three examinations over three years: one functional test (visual field) and two anatomical tests (OCTa and OCTrnfl). Glaucoma is a chronic disease that leads to vision loss, and understanding the vascular changes around the optic nerve could provide insights into disease progression. The study utilizes optical coherence tomography angiography (OCTa), a non-invasive imaging method that visualizes retinal blood flow, to assess changes in the peripapillary vascular plexus. By correlating these findings with visual field deficits, the study seeks to enhance monitoring and management of glaucoma.
Who should consider this trial
Good fit: Ideal candidates are men and women aged 18 and over with advanced glaucoma and a mean visual field deficit greater than 10 dB.
Not a fit: Patients with retinal vascular pathology, non-glaucomatous optic neuropathy, or significant environmental disorders affecting retinal imaging may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the understanding of glaucoma progression and lead to better monitoring and treatment strategies for patients.
How similar studies have performed: While there is limited research specifically analyzing OCTa in glaucoma, similar imaging techniques have shown promise in understanding vascular changes in other ocular conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men and women aged 18 and over * Patient with glaucoma followed in the ophthalmology department of Nantes University Hospital * mean visual field deficit (MD) \>10dB Exclusion Criteria: * Retinal vascular pathology (moderate to severe non-proliferative diabetic retinopathy, complicated diabetic retinopathy, OVCR/OBVR, OACR/OBAR, NOIAA...) Non-glaucomatous optic neuropathy, neurological pathology leading to visual field deficit (stroke with HLH, quadranopsia, chiasmatic Sd...) * PPR (retinal PanPhotocoagulation), retinal cerclage * Retinal pathology leading to visual field impairment (e.g. retinitis pigmentosa) * AMD and other macular pathologies that can lead to central visual field deficits * Significant environmental disorders impairing retinal imaging (e.g. active uveitis, dense cataract) * Loss of fixation point preventing visual field formation Pregnant or breast-feeding women * Protected adults under guardianship or curatorship * with unreliable visual fields (false positives and false negatives \> 33%) * with an uninterpretable OCTrnfl or OCTa (artifact, low quality score)
Where this trial is running
Nantes and 1 other locations
- CHU Nantes — Nantes, France (Recruiting)
- Jean-Baptiste Ducloyer — Nantes, France (Not_yet_recruiting)
Study contacts
- Study coordinator: Jean-Baptiste Ducloyer, M.D
- Email: jeanbatiste.ducloyer@chu-nantes.fr
- Phone: 02 40 08 34 01
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.